Bone mineral density during treatment of central precocious puberty.
Treatment of adults with gonadotropin releasing hormone analogs has resulted in rapid loss in bone mineral density (BMD). We measured lumbar and femoral neck BMD by dual-energy x-ray absorptiometry during 2 years of depot leuprolide therapy in 13 girls (mean age, 7.5 years; mean bone age, 10.9 years). At baseline, BMD was elevated for age and concordant with the advanced skeletal age. During therapy with gonadotropin releasing hormone analog, BMD values increased and BMD standard deviation scores for age and skeletal age did not change.
D015502:Absorptiometry, Photon / Q000295:instrumentation / Q000379:methods / Q000706:statistics & numerical data; D000365:Age Determination by Skeleton; D015519:Bone Density / Q000187:drug effects*; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage / Q000009:adverse effects; D008137:Longitudinal Studies; D011629:Puberty, Precocious / Q000188:drug therapy* / Q000503:physiopathology; D013997:Time Factors
D003692:Delayed-Action Preparations; D016729:Leuprolide